Bactolife secures over €30m in Series B funding to commercialise Binding Proteins

Gut health solutions company Bactolife has successfully raised over €30 million in its Series B investment round.

The funding will enable the company to commercialise its innovative Binding Proteins, a new food, feed and dietary supplement ingredient, and execute its human study programme, aimed at transforming human and animal health for proactive health management.

This significant financing round was led by Cross Border Impact Ventures (CBIV) and EIFO (Danish Export and Investment Fund), alongside continued support from existing investors Novo Holdings and Athos.

With the backing of cornerstone investors, Bactolife is now poised to launch its first Binding Protein products under the ingredient brand, Helm for human health in the United States in 2026.

The company plans to expand into Asia and Europe in the years that follow, with a strong commitment to ensuring the technology is accessible to women and children in low- and middle-income countries (LMICs).

Sebastian Søderberg, CEO of Bactolife, said: “Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026.

“This funding will enable us to clinically validate, scale, and commercialise our Binding Proteins, taking Bactolife’s solutions to a broad audience.

“We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission.

“We are ready to transform gut health with novel Binding Proteins.”

The proceeds from this round will be directed toward several key areas of growth for Bactolife, including the execution of its human study program across the US, EU, Asia, and LMICs.

In addition, the company plans to scale its manufacturing and supply operations to meet global demand with a strong emphasis on commercialisation of both human and animal health ingredients for dietary supplements, functional food and beverages, and feed additives.

Donna Parr, Managing Partner at Cross Border Impact Ventures, said: “We are thrilled to lead Bactolife’s Series B. Bactolife’s Binding Proteins have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition.

“At the same time, we are excited about the significant growth opportunity across North America, Europe, and Asia where the market opportunity is massive.

“This investment reflects our conviction that evidence-based technologies can reach massive high-growth markets, inclusive of people who need them most, and we look forward to partnering with Bactolife to accelerate clinical validation, scale manufacturing, and expand equitable access globally.”